Healthcare Global Enterprises Limited Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
INR 376.00
(+4.62%)
Based on the Healthcare Global Enterprises Limited stock forecast from 4 analysts, the average analyst target price for Healthcare Global Enterprises Limited is INR 376.00 over the next 12 months. Healthcare Global Enterprises Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Healthcare Global Enterprises Limited is Bearish, which is based on 3 positive signals and 10 negative signals. At the last closing, Healthcare Global Enterprises Limited’s stock price was INR 359.40. Healthcare Global Enterprises Limited’s stock price has changed by -4.45% over the past week, -2.12% over the past month and +15.77% over the last year.
No recent analyst target price found for Healthcare Global Enterprises Limited
No recent average analyst rating found for Healthcare Global Enterprises Limited
Company Overview Healthcare Global Enterprises Limited
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer and fertility. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates multi-specialty hospitals under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat; operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine, and pulmonary and critical care. In addition, the company offers medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. It operates cancer centers. The company was founded in 1989 and is based in Bengaluru, India. Read Less
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer and fertility. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment servi...Read More
Frequently Asked Questions About Healthcare Global Enterprises Limited (HCG:NSE) Stock
Based on ratings from 4 analysts Healthcare Global Enterprises Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on HCG:NSE's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for HCG:NSE is INR 376.00 over the next 12 months. The maximum analyst target price is INR 410 while the minimum anlayst target price is INR 330.
HCG:NSE stock's Price/Earning ratio is 169.80.
Our analysis grades HCG:NSE stock's Price / Earning ratio at F. This means that HCG:NSE stock's Price/Earning ratio is above 93% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this HCG:NSE may be a overvalued for its sector.
The last closing price of HCG:NSE's stock was INR 359.40.
The most recent market capitalization for HCG:NSE is INR 52.26B.
Based on targets from 4 analysts, the average taret price for HCG:NSE is projected at INR 376.00 over the next 12 months.
This means that HCG:NSE's stock price may go up by +4.62% over the next 12 months.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HCG:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
